Liposomes in Leishmaniasis: The Lysosome Connection

Alving, Carl R.; Weldon, John S.; Munnell, J. F.; Hanson, William L.

doi:10.1007/978-1-4684-4862-7_17

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This clearance was a function of the magnitude of the antibody level and resulted in increased tissue uptake by the liver, which also represents the principal site of deposition of injected liposomes in nonimmune mice (11). Passive antibodies specific for liposome-bound ligands may augment clearance kinetics of the liposomes, which may be of value in treatment of fungal (17) or parasitic infections (18) or in the activation of tumoricidal macrophages (19). Liposomes are known to interact with complement in addition to, or as a consequence of, fixation of antibody (21).…”

Section: Discussionmentioning

confidence: 99%

“…Depending to some extent on their composition and size, liposomes may be efficiently cleared from the circulation, notably by fixed macrophages of the liver, spleen, and lung (11). This property has been useful for the delivery of liposome-encapsulated drugs to the RES, as for the treatment offungal (17) or parasitic infections (18) and for augmenting the tumoricidal activity of macrophages (19), but is an undesirable characteristic when the target cells are not macrophages. Natural antibodies to liposome components exist in some species (20) and liposomes may interact directly, or via C reactive protein, with complement components (21) or with other uncharacterized serum proteins (22).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

Aragnol¹,

Leserman²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

In a study designed to evaluate the potential for in vivo manipulation of the circulation and tissue distribution of injected liposomes, mice were passively injected with antidinitrophenyl (anti-DNP) monoclonal antibodies of the IgG2a or IgG2b subclasses or were immunized with the nitrophenyl hapten bound to a protein carrier. They were then injected i.v. with 12'I-and carboxyfluorescein-labeled, DNPbearing liposomes. Circulation time of the DNP-bearing liposomes was markedly reduced in actively and passively immune mice, with increased deposition of liposomes in the liver. The increased clearance of liposomes could be abrogated by injection of a monoclonal antibody directed against the murine IgG Fc receptor (2.4G2). The results suggest that clearance of ligand-bearing reagent in the face of an immune response may be modified by specific immunologic manipulation in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

Aragnol¹,

Leserman²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

Liposomes as drug delivery system in the treatment of infectious diseases potential applications and clinical experience

Coune

1988

Infection

View full text Add to dashboard Cite

Liposomes are microscopic, closed lipid vesicles able to entrap hydrophilic as well as lipophilic compounds. They constitute a versatile drug delivery system. When injected by the intravenous route, liposomes are taken up by macrophages in the liver and in the spleen. Investigation of several animal models of infections has shown that liposome-entrapped anti-infectious drugs are active against infections due to facultative intracellular bacteria, parasites such as Leishmania, viruses such as the one causing Rift valley fever. Liposomes of different lipid compositions, structures and sizes were used for intravenous administration of anti-infectious drugs without inducing toxicity in the tested animals. Clinical experience was obtained with two different liposomal preparations of amphotericin B in the treatment of systemic fungal diseases in cancer patients; these preparations were shown to be effective and very well-tolerated.

show abstract

Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

Gupta

Dube

Vyas

2007

Journal of Drug Targeting

View full text Add to dashboard Cite

Amphotericin B (AmB) was formulated in trilaurin-based emulsomes (nanosize lipid particles) stabilized by soya phosphatidylcholine (PC), as a new delivery system for macrophage targeting for the treatment of visceral leishmaniasis (VL). Emulsomes were modified by coating them with macrophage-specific ligand (O-palmitoyl mannan, OPM). The antileishmanial activity of AmB-deoxycholate (AmB-Doc) and emulsome entrapped AmB was tested in vitro in Leishmania donovani infected macrophage-amastigote system (J774A.1 cells), which showed higher efficacy of OPM grafted AmB emulsomes (TLEs-OPM) over plain AmB emulsomes (TLEs) and AmB-Doc. The in vivo antileishmanial activity of the AmB (0.5 mg/kg) was tested in AmB-Doc, TLEs and TLEs-OPM forms against VL in L. donovani infected hamsters. Formulation TLEs-OPM eliminated intracellular amastigotes of L. donovani within splenic macrophages more efficiently (73.7 +/- 6.7% parasite inhibition) than the formulation TLEs (51.7 +/- 5.4% parasite inhibition) (P < 0.01) or AmB-Doc (30.4 +/- 4.8% parasite inhibition) (P < 0.001). Our results suggest that these newer formulations (plain and ligand appended emulsomes) are a promising alternative to the conventional AmB-Doc formulation for the treatment of VL.

show abstract

Liposomes in Leishmaniasis: The Lysosome Connection

Cited by 6 publications

References 18 publications

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.

Liposomes as drug delivery system in the treatment of infectious diseases potential applications and clinical experience

Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

Contact Info

Product

Resources

About